HYRNUO (Sevabertinib) Patent Expiration, LOE Window & CMS Spending

HYRNUO (Sevabertinib) by Bayer: FDA Orange Book core substance LOE 2043-11-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $24,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN219972 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-11-14
Last Listed Patent or Exclusivity Date2043-11-14
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($24,000 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.